Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:

Canaccord Genuity 44^th Annual Growth Conference
Format: Management will participate in a presentation and investor meetings
Date: Tuesday, August 13, 2024
Presentation Time: 8:00 a.m. ET
Location: Boston, MA

15^th Annual Wedbush PacGrow Healthcare Conference
Format: Management will participate in investor meetings
Date: Wednesday, August 14, 2024
Location: New York City, NY

A live webcast of the presentation will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
[email protected]

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
[email protected]

You May Also Be Interested In

• RCM Technologies, Inc. Announces Second Quarter 2026 Results
• Madison Pacific Properties Inc. announces the results for the six months ended June 30, 2026 and declares dividend
• Condor Announces 2026 Second Quarter Results